{
    "eid": "2-s2.0-84930032118",
    "title": "Pyrosequencing analysis of KRAS codon 61 mutations in Thai patients with advanced colorectal cancer",
    "cover-date": "2015-02-01",
    "subject-areas": [
        {
            "$": "General Biochemistry",
            "@code": "1300"
        },
        {
            "$": "General Medicine",
            "@code": "2700"
        }
    ],
    "keywords": [
        "Colorectal cancer",
        "KRAS",
        "Mutation",
        "Pyrosequencing",
        "Targeted therapy"
    ],
    "authors": [
        "Chinachote Teerapakpinyo"
    ],
    "citedby-count": 1,
    "ref-count": 26,
    "ref-list": [
        "Implications for KRAS status and EGFR-targeted therapies in metastatic CRC",
        "Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab",
        "Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer",
        "Drug therapy: EGFR antagonists in cancer treatment",
        "Transformation Efficiency of RasQ61 Mutants Linked to Structural Features of the Switch Regions in the Presence of Raf",
        "Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins",
        "KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer",
        "KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial",
        "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer",
        "Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials",
        "Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS",
        "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer",
        "Molecular markers in the treatment of metastatic colorectal cancer",
        "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer",
        "Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer",
        "PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer",
        "PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients",
        "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies",
        "A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients",
        "Sanger sequencing in routine KRAS testing: A review of 1720 cases from a pathologist's perspective",
        "KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer",
        "Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics",
        "Mutation detection by real-time PCR: A simple, robust and highly selective method",
        "Sensitive sequencing method for KRAS mutation detection by pyrosequencing",
        "K-ras mutation detection in colorectal cancer using the Pyrosequencing technique",
        "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "affilname": "Chulalongkorn University",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Chulalongkorn University"
    ]
}